SCHEMBL3532837

SCHEMBL3532837

O=S(=O)(Nc1ccc(Cl)nc1I)c1ccc2ncsc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLO1 Q04760 1/20 0.57
ALDH1A1 P00352 3/20 0.51
PKM P14618 2/20 0.51
AKT1 P31749 1/20 0.50
PIK3CA P42336 1/20 0.50
MTOR P42345 1/20 0.50
PTPN2 P17706 3/20 0.47
PTPN1 P18031 3/20 0.47
PTPN5 P54829 3/20 0.47
HSPD1 P10809 1/20 0.47
HSPE1 P61604 1/20 0.47
CCKBR P32239 1/20 0.46
IKBKB O14920 3/20 0.44
CHUK O15111 2/20 0.44
BRD4 O60885 1/20 0.43
PIK3CD O00329 2/20 0.42
POLB P06746 2/20 0.41
RXFP1 Q9HBX9 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30640626 0.83 GLO1 (0.55) GLO1ALDH1A1PKMAKT1PIK3CA
SCHEMBL2766050 0.83 GLO1 (0.55) GLO1ALDH1A1PKMAKT1PIK3CA
SCHEMBL3536720 0.79 ALDH1A1 (0.52) GLO1ALDH1A1PIK3CAPOLBMEN1
SCHEMBL3531098 0.78 GLO1 (0.56) GLO1ALDH1A1PKMAKT1PIK3CA
SCHEMBL3528111 0.77 GLO1 (0.46) GLO1ALDH1A1PKMAKT1PIK3CA
SCHEMBL3530734 0.75 PPARG (0.45) GLO1ALDH1A1PKMAKT1PIK3CA
SCHEMBL2764836 0.74 GLO1 (0.55) GLO1ALDH1A1PKMAKT1PIK3CA
SCHEMBL3535146 0.74 SLC40A1 (0.61) GLO1PKMPIK3CAPIK3CDPOLB
SCHEMBL9930583 0.74 CCR2 (0.69) GLO1ALDH1A1PKMCCR2
SCHEMBL3530032 0.73 APP (0.42) ALDH1A1PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7728002-B2 Use of pyrrolopyridine compounds for activating PPAR receptors and treatment of conditions involving such receptors LABORATOIRES FOURNIER S.A. (FR) 2010-06-01 US disclosed
US-20090239856-A1 Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors LABORATOIRES FOURNIER S.A. (FR) 2009-09-24 US disclosed
EP-1919474-B1 PYRROLOPYRIDINE DERIVATIVES AND USE OF SAME AS PPAR RECEPTOR MODULATORS FOURNIER LAB SA (FR) 2009-08-05 EP disclosed
US-7557122-B2 Pyrrolopyridine compounds, method of making them and uses thereof LABORATOIRES FOURNIER S.A. (FR) 2009-07-07 US disclosed
US-20080200495-A1 Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239856-A1 Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors PPARD, PPARA, PPARG GLO1 4133/4885ALDH1A1 1314/4885PKM 445/4885
US-20080200495-A1 Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof LIPG, PCSK9, PNLIP GLO1 655/4885ALDH1A1 1350/4885PKM 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.